5057-51-2

Basic information

• Product Name: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID
• Synonyms: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID;Butanoic acid, 4-(3-chlorophenoxy)-
• CAS NO: 5057-51-2
• Molecular Formula: C₁₀H₁₁ClO₃
• Molecular Weight: 214.65
• Mol File: 5057-51-2.mol

Chemical Properties

• Boiling Point: 383.1°C at 760 mmHg
• Flash Point: 185.5°C
• Appearance: /
• Density: 1.266g/cm³
• Vapor Pressure: 1.49E-06mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID(5057-51-2)
• EPA Substance Registry System: 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID(5057-51-2)

Safety Data

• Hazardous Substances Data: 5057-51-2(Hazardous Substances Data)

Usage

Uses

Used in Agriculture:
4-(3-CHLORO-PHENOXY)-BUTYRIC ACID is used as a plant growth regulator for promoting root development in various crops. It is applied to seeds, cuttings, or transplants to encourage robust root systems, which in turn supports improved plant growth and yield.
Used in Seed Treatment:
4-(3-CHLORO-PHENOXY)-BUTYRIC ACID is used as a seed treatment to enhance the germination process and root establishment, leading to stronger and more resilient seedlings.
Used in Horticulture:
In horticulture, 4-(3-CHLORO-PHENOXY)-BUTYRIC ACID is used as a growth stimulant to improve the health and vigor of ornamental plants, ensuring lush growth and increased resistance to environmental stressors.
Used in Post-Harvest Storage:
4-(3-CHLORO-PHENOXY)-BUTYRIC ACID is studied for its potential use in controlling unwanted sprouting in stored potatoes, helping to maintain the quality and extend the shelf life of the produce.
Used in Weed Management:
4-(3-CHLORO-PHENOXY)-BUTYRIC ACID is considered for use as a herbicide to control the growth of certain weeds, offering an alternative method for managing unwanted plant species in agricultural settings.

InChI:InChI=1/C10H11ClO3/c11-8-3-1-4-9(7-8)14-6-2-5-10(12)13/h1,3-4,7H,2,5-6H2,(H,12,13)

Upstream product

• 64-17-5 ethanol 
• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 37142-46-4 1-(3-bromopropoxy)-3-chlorobenzene 
• 96-48-0 4-butanolide 
• 108-43-0 3-monochlorophenol 
• 108-37-2 1-bromo-3-chlorobenzene 
• 95-57-8 2-monochlorophenol 
• 37483-53-7 ethyl 4-(3-chlorophenoxy)butanoate 
• 5057-52-3 4-(2-chlorophenoxy)butanoic acid 
• 111105-19-2 ethyl 4-(2-chlorophenoxy)butanoate 

Downstream Products

• 37483-57-1 8-chloro-1-oxo-2,3,4,5-tetrahydrobenzocycloheptan-5-one 
• 1240998-36-0 8-chloro-1-(2,4-dichlorophenyl)-N-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl-methyl)-4,5-dihydrobenzo-1H-6-oxa-cyclohepta[1,2-c]pyrazole-3-carboxamide 
• 37589-67-6 4-(3-Chloro-phenoxy)-N-(2-diethylamino-ethyl)-butyramide 
• 37483-56-0 N,N-Diethyl-4-(3-chlorphenoxy)buttersaeureamid 
• 37483-55-9 4-(3-Chlorphenoxy)buttersaeureamid 
• 124392-84-3 8-Chloro-3-(4-methoxy-phenyl)-2-phenyl-4,5-dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulene 
• 124392-69-4 8-Chloro-4-[1-(4-methoxy-phenyl)-meth-(E)-ylidene]-3,4-dihydro-2H-benzo[b]oxepin-5-one 
• 37483-54-8 4-(3-Chlorphenoxy)buttersaeurechlorid 
• 37483-53-7 ethyl 4-(3-chlorophenoxy)butanoate 

Relevant articles and documents

Design, synthesis, and biological evaluation of 3-amino-2-oxazolidinone derivatives as potent quorum-sensing inhibitors of Pseudomonas aeruginosa PAO1

Due to the increasing resistance of Pseudomonas aeruginosa to most clinically relevant antimicrobials, it is challenging to treat bacterial infection with traditional antibiotics. Quorum sensing can regulate the production of biofilms and virulence factors which are closely related to bacterial resistance. Previously we synthesized a series of oxazolidinone compounds targeting the quorum-sensing transcriptional regulatory protein CviR and ZS-12 showed good activity against Chromobacterium violaceum CV026 quorum-sensing. In this study, eighteen 3-amino-2-oxazolidinone compounds were designed and synthesized using ZS-12 as the lead compound. We initially evaluated the inhibitory activities of novel oxazolidinone compounds against QS using C. violaceum CV026 as a reporter strain. Thirteen compounds showed good activities (IC50 range 3.69–63.58 μM) and YXL-13 inhibition was the most significant (IC50 = 3.686 ± 0.5790 μM) against biofilm formation and virulence factors determination of P. aeruginosa PAO1. In vitro, YXL-13 significantly inhibited the formation of PAO1 biofilm (range 42.98%–17.67%), the production of virulence factors (pyocyanin, elastase, rhamnolipid, and protease), and bacterial motility. Moreover, the combination of YXL-13 with an antibiotic (meropenem trihydrate) could significantly improve the antibiotic susceptibility of biofilm P. aeruginosa PAO1 cells. In vivo, YXL-13 significantly prolonged the lifespan of wildtype Caenorhabditis elegans N2 infected by P. aeruginosa PAO1. In conclusion, YXL-13 is a candidate agent for antibiotic-resistant P. aeruginosa PAO1and provides a method for finding new antibacterial drugs.

Development of oxygen-bridged pyrazole-based structures as cannabinoid receptor 1 ligands

In this work, the synthesis of the cannabinoid receptor 1 neutral antagonists 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4,5-dihydrobenzo-1H-6-oxa-cyclohepta[1,2-c] pyrazole-3-carboxamide 1a and its deaza N-cyclohexyl analogue 1b has led to a deepening of the structure-activity studies of this class of compounds. A series of novel 4,5-dihydrobenzo-oxa-cycloheptapyrazoles analogues of 1a,b, derivatives 1c-j, was synthesized, and their affinity towards cannabinoid receptors was determined. Representative terms were evaluated using in vitro tests and isolated organ assays. Among the derivatives, 1d and 1e resulted in the most potent CB1 receptor ligands (KiCB1 = 35 nM and 21.70 nM, respectively). Interestingly, both in vitro tests and isolated organ assays evidenced CB1 antagonist activity for the majority of the new compounds, excluding compound 1e, which showed a CB1 partial agonist behaviour. CB1 antagonist activity of 1b was further confirmed by a mouse gastrointestinal transit assay. Significant activity of the new CB1 antagonists towards food intake was showed by preliminary acute assays, evidencing the potentiality of these new derivatives in the treatment of obesity.

Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models

The persistent reservoir of cells latently infected with human immunodeficiency virus (HIV)-integrated proviral DNA necessitates lifelong suppressive antiretroviral therapy (ART). Epigenetic targeted compounds have shown promise as potential latency-reversing agents; however, these drugs have undesirable toxicity and lack specificity for HIV. We utilized a novel HEK293-derived FlpIn dual-reporter cell line, which quantifies specific HIV provirus reactivation (LTR promoter) relative to nonspecific host cell gene expression (CMV promoter), to identify the 5-substituted 2-acylaminothiazole hit class. Here, we describe the optimization of the hit class, defining the functionality necessary for HIV gene activation and for improving in vitro metabolism and solubility. The optimized compounds displayed enhanced HIV gene expression in HEK293 and Jurkat 10.6 latency cellular models and increased unspliced HIV RNA in resting CD4+ T cells isolated from HIV-infected individuals on ART, demonstrating the potential of the 2-acylaminothiazole class as latency-reversing agents.

Pharmaceutical compounds wiht angiogenesis inbhibitory activity

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A' are as defined in the description. B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3-, SO3H, COO-, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

PHARMACEUTICAL COMPOUNDS

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A′ are as defined in the description.B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3?, SO3H, COO?, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

Copper(ii)-catalyzed C-O coupling of aryl bromides with aliphatic diols: Synthesis of ethers, phenols, and benzo-fused cyclic ethers

A highly efficient copper-catalyzed C-O cross-coupling reaction between aryl bromides and aliphatic diols has been developed employing a cheaper, more efficient, and easily removable copper(ii) catalyst. A broad range of aryl bromides were coupled with aliphatic diols of different lengths using 5 mol% CuCl2 and 3 equivalents of K2CO3 in the absence of any other ligands or solvents to afford the corresponding hydroxyalkyl aryl ethers in good to excellent yields. In this newly developed protocol, aliphatic diols have multilateral functions as coupling reactants, ligands, and solvents. The resulting hydroxyalkyl aryl ethers were further readily converted into the corresponding phenols, presenting a valuable alternative way to phenols from aryl bromides. Furthermore, it was demonstrated that they are useful intermediates for more advanced molecules such as benzofurans and benzo-fused cyclic ethers. This journal is

PHARMACEUTICAL COMPOSITIONS

Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggr

Tricyclic condensed pyrazole derivatives as CB1 inhibitors

Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring rcomprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous sy

Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors

Microemulsions of pharmaceutical compositions comprising the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers forming organized structures as: aggreg

PHARMACEUTICAL COMPOUNDS

Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.